早期给予高压盐水溶液的效果在急性减补性心力衰竭中
Tugce Colluoglu1, Tuğba Kapanşahin1, Melahat Hicran Aksu1
1Karabuk University, Faculty of Medicine, Department of Cardiology, Karabuk - Turquia.
Arquivos brasileiros de cardiologia
|July 17, 2024
概括
高血压盐溶液 (HSS) 与循环利尿剂 (LD) 结合,可为急性不补偿性心力衰竭 (ADHF) 提供安全有效的利尿. 这种初始治疗方法没有损害功能,并导致患者住院时间缩短.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學.
- 药理学 药理学是指药理学的学科.
背景情况:
- 关于初始使用高血压盐溶液 (HSS) 治疗急性不补偿性心力衰竭 (ADHF) 的证据有限.
- 研究新的治疗策略对于改善ADHF患者的治疗结果至关重要.
研究的目的:
- 评估启动高血压盐溶液 (HSS) 与循环利尿剂 (LD) 作为ADHF患者的第一线利尿治疗的影响.
- 评估对功能,电解质平衡和临床结果的影响.
主要方法:
- 一项回顾性病例控制研究,涉及171名被诊断患有ADHF的成年患者.
- 患者被分为两组:一组接受HSS+LD的前期组合治疗,另一组接受标准化的LD单疗法.
- 主要终点是功能恶化 (WRF);次要终点包括因心力衰竭住院治疗和6个月的随访期间因任何原因死亡率.
主要成果:
- 与LD组相比,预先HSS+LD组在第一天和第二小时分别表现出明显更高的尿液和自然尿液.
- 虽然血清 (Na+) 在HSS+LD组增加,但关键的功能标志物,如膜过率 (GFR) 和肌素保持稳定.
- 在HSS+LD组中,功能恶化 (WRF) 的发生频率较低 (16.1%与35.5%,p=0.007),住院时间较短 (4天与5天,p=0.004).
结论:
- 启动高血压盐溶液 (HSS) 与循环利尿剂 (LD) 结合似乎是ADHF中利尿症的安全有效策略.
- 这种组合疗法似乎不会损害功能,可能导致医院住院时间缩短.
- 需要进一步的前性研究来证实这些发现并优化治疗方案.
相关概念视频
01:22Heart Failure Drugs: Diuretics
361
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
361
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
418
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
418
01:26Heart Failure Drugs: Inotropic Agents
563
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
563
01:16Tonicity in Animals
3.1K
Tonicity describes the amount of solute in a solution. The measure of the tonicity of a solution, or the total amount of solutes dissolved in a specific amount of solution, is called its osmolarity. Three terms—hypotonic, isotonic, and hypertonic—are used to relate the osmolarity of a cell to the osmolarity of the extracellular fluid that contains the cells. In a hypotonic solution, such as tap water, the extracellular fluid has a lower concentration of solutes than the fluid inside...
3.1K
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:22Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336